Olga Kifor

TL;DR: Whether the MCF-7 and MDA-MB-231 human breast cancer cell lines express the CaR and whether CaR agonists modulate PTHrP secretion is investigated, which could potentially participate in a vicious cycle in which PTHRP-induced bone resorption raises the levels of Ca2+(o) and TGFbeta within the bony microenvironment, which then act in concert to evoke further P THrP release and worsening osteolysis.

TL;DR: The extracellular Ca2+ (Cao2+)‐sensing receptor (CaR) is a G protein–coupled receptor that activates phospholipase C (PLC), providing for coordinate, receptor‐mediated regulation of multiple signal transduction pathways in parathyroid and presumably other CaR‐expressing cells.

TL;DR: Sr(2+) is a full CaR agonist in HEK-CaR and POB, and, therefore, the anabolic effect of Sr( 2+) on bone in vivo could be mediated, in part, by the CaR.

TL;DR: This animal model of human primary hyperparathyroidism provides direct experimental evidence that overexpression of the cyclin D1 oncogene can drive excessive parathyroid cell proliferation and that this proliferative defect need not occur solely as a downstream consequence of a defect in parathyro hormone secretory control by serum calcium.

TL;DR: The studies indicate that the CaR is present in low‐density mononuclear bone marrow cells as well as in cells of several hematopoietic lineages and could potentially play a role in controlling the function of various cell types within the marrow space.